Sugar intake / metabolism / reward inhibiting agent and use thereof

The use of specific lactic acid bacteria and bifidobacteria strains in a control agent addresses the challenge of excessive sugar intake by inducing natural sugar preference, reducing artificial sweetener consumption, and improving glucose tolerance, effectively managing lifestyle-related diseases.

WO2024237318A1PCT designated stage expired Publication Date: 2024-11-21KEIO UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018181
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-16
Filing Date
2024-05-16
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Excessive sugar intake, particularly of artificial sweeteners, contributes to lifestyle-related diseases such as type 2 diabetes mellitus and obesity, and existing artificial sweeteners paradoxically worsen these conditions due to complex nutrient sensing mechanisms, highlighting the need for controlling sugar preference and metabolism.

Method used

A control agent containing lactic acid bacteria or bifidobacteria, specifically strains like Lactobacillus casei, Enterococcus gallinarum, Bifidobacterium pseudolongum, and Bifidobacterium pseudocatenulatum, which induce sugar preference by metabolizing glucose and producing acetic acid, thereby regulating the brain's reward system and improving glucose tolerance.

Benefits of technology

The agent effectively restores sugar preference, reduces artificial sweetener intake, and improves glucose tolerance, offering a preventive or therapeutic effect on lifestyle-related diseases by modulating the gut-brain axis and sugar metabolism.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018181_21112024_PF_FP_ABST
    Figure JP2024018181_21112024_PF_FP_ABST
Patent Text Reader

Abstract

This sugar intake / metabolism / reward inhibiting agent having lactic acid bacteria as an active ingredient is useful for controlling sugar palatability.
Need to check novelty before this filing date? Find Prior Art

Description

Agents for controlling sugar intake, metabolism and reward and their use

[0001] The present invention relates to an agent for controlling sugar intake, metabolism, and reward, and uses thereof. This application claims priority to U.S. Provisional Application No. US63 / 502,433 filed May 16, 2023, the contents of which are incorporated herein by reference.

[0002] Animals prefer nutritious sugars necessary for biological functions over artificial sweeteners with no nutritional value, a phenomenon known as sugar preference (SP). Recent studies have revealed that enteroendocrine cells (EECs) play an important role in establishing sugar preference (see, for example, Non-Patent Documents 1 and 2).

[0003] On the other hand, excessive sugar intake is one of the major causes of type 2 diabetes mellitus (T2DM). Non-nutritive artificial sweeteners were initially intended to prevent T2DM and obesity by reducing sugar intake, but they may paradoxically exacerbate these diseases, highlighting the complexity of nutrient sensing of sugar and artificial sweeteners. Therefore, controlling artificial sweetener intake and acquiring sugar preference to promote normal sugar intake and metabolism are important challenges.

[0004] While taste buds detect sweet sugars and artificial sweeteners using chemosensory taste receptors (T1R2 / T1R3), the intestine has a different glucose sensor system that allows it to distinguish between nutritious sugars and artificial sweeteners (see, for example, Non-Patent Document 1).

[0005] The intestinal epithelium digests simple carbohydrates into glucose via the sodium ion-dependent glucose transporter 1 (SGLT1), which is expressed in intestinal absorptive cells, and delivers it to the absorptive cells of the small intestine. SGLT1 is also expressed in EECs and plays a role in glucose sensing in the SP.

[0006] SGLT1-mediated glucose stimulation in EECs was mediated by Ca 2+It is believed that glucose induces influx and releases neurotransmitters in the synaptic space between interconnected afferent neurons, and that the brain's reward system responds to ascending signals via these glucose-dependent afferent autonomic nerves, establishing SP.

[0007] Tan HE, et al., The Gut-Brain Axis Mediates Sugar Preference, Nature, 580 (7804), 511-516, 2020.Buchanan KL, The preference for sugar over sweetener depends on a gut sensor cell, Nature Neuroscience, 25, 191-200, 2022.

[0008] However, the mechanism of sugar preference (SP), which is necessary for normal biological functions, remains unclear. The present invention aims to clarify the mechanism of SP and provide a technique for controlling SP.

[0009] The present invention includes the following aspects: [1] A regulator of sugar intake, metabolism, and reward, comprising lactic acid bacteria or bifidobacteria as an active ingredient. [2] The regulator of sugar intake, metabolism, and reward according to [1], wherein the lactic acid bacteria or bifidobacteria are bacteria having the genome structure shown in Figure 27. [3] The regulator of sugar intake, metabolism, and reward according to [2], wherein the lactic acid bacteria are bacteria of the genus Lactobacillus or Enterococcus, and the bifidobacteria are bacteria of the genus Bifidobacterium. [4] The Lactobacillus bacterium is Lactobacillus casei (Lc), the Enterococcus bacterium is Enterococcus gallinarum (Eg), and the Bifidobacterium bacterium is Bifidobacterium pseudolongum (Bp), Bifidobacterium pseudocatenulatum (Bpc), or Bifidobacterium bifidum (Bp). [5] The sugar intake, metabolism, and reward regulator according to any one of [1] to [4], which has a preventive or therapeutic effect on lifestyle-related diseases. [6] A food composition for preventing or ameliorating lifestyle-related diseases, comprising the sugar intake, metabolism, and reward regulator according to any one of [1] to [4].

[0010] According to the present invention, a technique can be provided for controlling sugar preference and thereby controlling sugar intake, metabolism, and reward.

[0011] FIG. 1 is a schematic diagram outlining Experimental Example 1 and a graph showing the results. FIG. 2 is a schematic diagram outlining Experimental Example 2 and a graph showing the results. FIG. 3 is a graph showing the results of Experimental Example 3. FIG. 4 is a schematic diagram outlining Experimental Example 4 and a graph showing the results. FIG. 5 is a graph showing the results of Experimental Example 5. FIG. 6 is a schematic diagram outlining Experimental Example 6 and a graph showing the results. FIG. 7 is a graph showing the results of Experimental Example 8. FIG. 8 is a graph showing the results of Experimental Example 8. FIG. 9 is a schematic diagram outlining Experimental Example 8 and a graph showing the results. FIG. 10 is a graph showing the results of Experimental Example 9. FIG. 11 is a graph showing the results of Experimental Example 10. FIG. 12 is a graph showing the results of Experimental Example 11. FIG. 13 is a graph showing the results of Experimental Example 11. FIG. 14 is a graph showing the results of Experimental Example 11. FIG. 15 is a graph showing the results of Experimental Example 11. FIG. 16 is a graph showing the results of Experimental Example 12. FIG. 17 is a scanning electron microscope image taken in Experimental Example 13. FIG. 18 is a graph showing the results of Experimental Example 13. FIG. 19 is a graph showing the results of Experimental Example 13. FIG. 20 is a graph showing the results of Experimental Example 14. FIG. 21 is a schematic diagram outlining Experimental Example 15 and a graph showing the results. FIG. 22 is a graph showing the results of Experimental Example 17. FIG. 23 is a schematic diagram outlining Experimental Example 18 and a graph showing the results. FIG. 24 is a graph showing the results of Experimental Example 19. FIG. 25 is a graph showing the results of Experimental Example 19. FIG. 26 is a graph showing the results of Experimental Example 19. FIG. 27 is a diagram showing the genome structure of transporter genes and gene location information possessed by each bacterium, based on the results of whole genome sequence analysis of Bp, Eg, and Bpc. FIG. 28 is a schematic diagram outlining Experimental Example 16 and a graph showing the results. FIG. 29 is a schematic diagram summarizing this study. FIG. 30 is a graph showing the results of Experimental Example 20. FIG. 31 is a graph showing the results of Experimental Example 20.

[0012] [Agent for Regulating Sugar Uptake, Metabolism, and Reward] In one embodiment, the present invention provides an agent for regulating sugar uptake, metabolism, and reward, which contains lactic acid bacteria or bifidobacteria as an active ingredient. Here, "regulating reward" refers to regulating the brain reward system.

[0013] By administering the sugar intake / metabolism / reward regulator of this embodiment to a human or non-human animal, sugar preference can be established and normal sugar intake can be induced. Therefore, the sugar intake / metabolism / reward regulator of this embodiment can also be referred to as a sugar preference inducer.

[0014] Non-human animals include not only mammals but also insects. As will be described later in the Examples, sugar preference is also conserved in Drosophila. Mammals include, for example, rodents such as mice, rats, hamsters, and guinea pigs; ungulates such as pigs, cows, goats, horses, and sheep; carnivores such as dogs and cats; and primates such as rhesus monkeys, cynomolgus monkeys, marmosets, orangutans, and chimpanzees.

[0015] As will be described later in the Examples section, the inventors have clarified the mechanism of glucose preference (SP), which is necessary for maintaining normal biological functions. Glucose preference-inducing bacteria present in the upper small intestine metabolize glucose to produce acetic acid, and the acetic acid-GPR41-Gαi-Ca 2+ Depolarizing EECs through the influx pathway results in neurotransmitter release in the synaptic spaces between EECs and interconnected neurons, and the brain's reward system then responds to these glucose-dependent autonomic afferents, establishing glucose preference.

[0016] The inventors have demonstrated for the first time that sugar-loving bacteria are involved in the establishment of SP. Sugar-loving bacteria are bacteria that can survive in the upper small intestine and metabolize glucose to produce acetic acid. The inventors have shown that sugar-loving bacteria include lactic acid bacteria and bifidobacteria.

[0017] Furthermore, as described later in the Examples, a decrease in sugar-preference-inducing bacteria was observed in the upper small intestine of high-fat diet-induced diabetic mice, and a loss of sugar preference was observed. Furthermore, supplementation of these mice with sugar-preference-inducing bacteria restored sugar preference, reduced artificial sweetener intake, and improved glucose tolerance.

[0018] Therefore, by administering lactic acid bacteria or bifidobacteria to a subject, it is possible to induce the establishment of sugar preference. Furthermore, by administering lactic acid bacteria or bifidobacteria to a subject, it is possible to improve diabetes. In the sugar preference inducer of this embodiment, the lactic acid bacteria or bifidobacteria must be live bacteria.

[0019] Examples of lactic acid bacteria or bifidobacteria include bacteria having the genome structure shown in FIG.

[0020] More specifically, lactic acid bacteria or bifidobacteria have a transporter for any sugar selected from the group consisting of galactose oligomers, maltooligosaccharides, raffinose, stachyose, melibiose, and multiple sugars.

[0021] The transporters for galactose oligomers and maltooligosaccharides are encoded by a combination of the GanO, GanP, GanQ, and MsmX genes.

[0022] The transporters for raffinose, stachyose, and melibiose are encoded by a combination of the MsmE, MsmF, MsmG, and MsmK genes.

[0023] The multiple sugar transporter is encoded by a combination of the ChvE, GguB, and GguA genes.

[0024] It is further preferred that the lactic acid bacteria or bifidobacteria possess a complete set of genes necessary for acetic acid production.

[0025] It is further preferred that the lactic acid bacteria or bifidobacteria possess a carbohydrate-degrading enzyme, such as glycoside hydrolase (GH) 3, GH43, GH13, GH51, GH29, GH32, or GH65.

[0026] As will be described later in the Examples, specific examples of lactic acid bacteria capable of inducing sugar preference include bacteria of the genus Lactobacillus and Enterococcus, and specific examples of bifidobacteria capable of inducing sugar preference include bacteria of the genus Bifidobacterium.

[0027] More specifically, the Lactobacillus bacteria include Lactobacillus casei (Lc). More specifically, the Enterococcus bacteria include Enterococcus gallinarum (Eg). More specifically, the Bifidobacterium bacteria include Bifidobacterium pseudolongum (Bp), Bifidobacterium pseudocatenulatum (Bpc), and Bifidobacterium bifidum (Bb).

[0028] The nucleotide sequence of the entire genome of Bifidobacterium pseudolongum (Bp) is shown in SEQ ID NO: 1 and 2. The nucleotide sequence of the entire genome of Bifidobacterium pseudocatenulatum (Bpc) is shown in SEQ ID NO: 3. The nucleotide sequence of the entire genome of Enterococcus gallinarum (Eg) is shown in SEQ ID NO: 4 to 6.

[0029] As will be described later in the Examples, high-fat diet-induced diabetic mice administered with the sugar intake / metabolism / reward regulator of this embodiment recovered sugar preference, reduced their intake of artificial sweeteners, and improved their glucose tolerance. Therefore, the sugar intake / metabolism / reward regulator of this embodiment has the effect of preventing or treating lifestyle-related diseases.

[0030] By administering the sugar intake / metabolism / reward regulator of this embodiment, sugar preference is improved in humans or non-human animals, thereby preventing or improving lifestyle-related diseases caused by excessive intake of artificial sweeteners.

[0031] The sugar intake / metabolism / reward regulator of this embodiment can also be described as a preventive or therapeutic agent for lifestyle-related diseases, which contains lactic acid bacteria or bifidobacteria as an active ingredient.

[0032] In this specification, "containing as an active ingredient" means containing as a main active ingredient, and means containing to an extent that an effect is exhibited. The "effect" referred to here includes an effect of inducing sugar preference, a preventive effect or a therapeutic effect against lifestyle-related diseases, etc.

[0033] Lifestyle-related diseases include diseases associated with the loss of sugar preference, more specifically diabetes, obesity, irritable bowel syndrome, bulimia, anorexia nervosa, depression, hypertension caused by obesity, non-alcoholic fatty liver disease, hyperlipidemia, arteriosclerosis, and thrombosis, for which excessive intake of artificial sweeteners is considered a risk factor.

[0034] Therefore, the sugar preference inducer of this embodiment can be referred to as a sugar preference improving agent, a sugar preference restoring agent, a preventive or therapeutic agent for diabetes, a preventive or therapeutic agent for obesity, a preventive or therapeutic agent for irritable bowel syndrome, a preventive or therapeutic agent for bulimia, a preventive or therapeutic agent for anorexia nervosa, a preventive or therapeutic agent for depression, a preventive or therapeutic agent for hypertension, a preventive or therapeutic agent for non-alcoholic fatty liver disease, a preventive or therapeutic agent for hyperlipidemia, a preventive or therapeutic agent for arteriosclerosis, a preventive or therapeutic agent for thrombosis, etc.

[0035] The sugar preference inducer of this embodiment may be formulated as a pharmaceutical composition containing a pharmaceutically acceptable carrier. The pharmaceutical composition of this embodiment can be administered orally in the form of, for example, a tablet, capsule, or liquid, or parenterally in the form of an enema.

[0036] Pharmaceutically acceptable carriers may be any carrier commonly used in the preparation of pharmaceutical compositions, without any particular limitations. More specifically, examples include binders such as atelocollagen, collagen, gelatin, cornstarch, tragacanth gum, and gum arabic; excipients such as starch and crystalline cellulose; swelling agents such as alginic acid; and solvents such as water, ethanol, and glycerin.

[0037] The pharmaceutical composition may contain additives, such as lubricants such as calcium stearate and magnesium stearate, sweeteners such as sucrose, lactose, saccharin and maltitol, flavorings such as peppermint and rhizome oil, stabilizers such as benzyl alcohol and phenol, buffers such as phosphates and sodium acetate, solubilizers such as benzyl benzoate and benzyl alcohol, antioxidants, and preservatives.

[0038] Pharmaceutical compositions can be formulated by appropriately combining the above-mentioned lactic acid bacteria or bifidobacteria, the above-mentioned pharmaceutically acceptable carriers and additives, and mixing them in a unit dosage form required for generally accepted pharmaceutical practice.

[0039] The dosage of the pharmaceutical composition varies depending on the symptoms, body weight, age, sex, etc. of the subject and cannot be determined in general, but in the case of oral administration, it is considered appropriate to administer, for example, 0.1 mg / kg body weight to 1 g / kg body weight, e.g., 0.5 to 100 mg / kg body weight, e.g., 0.5 to 50 mg / kg body weight, e.g., 0.5 to 20 mg / kg body weight of the active ingredient (lactic acid bacteria or bifidobacteria) per day. In addition, in the case of parenteral administration, it is considered appropriate to administer, for example, 0.1 mg / kg body weight to 1 g / kg body weight of the active ingredient (lactic acid bacteria or bifidobacteria) per day.

[0040] [Food Composition] In one embodiment, the present invention provides a food composition for preventing or ameliorating lifestyle-related diseases, comprising the sugar intake / metabolism / reward regulator described above. The food composition of this embodiment comprises lactic acid bacteria or bifidobacteria as an active ingredient. The lactic acid bacteria and bifidobacteria are the same as those described above. The food composition of this embodiment may further comprise other ingredients typically contained in food compositions.

[0041] Ingestion of the food composition of this embodiment improves sugar preference in humans or non-human animals, and has the effect of preventing or improving lifestyle-related diseases, such as those described above, including diabetes, obesity, irritable bowel syndrome, bulimia, anorexia nervosa, depression, hypertension, non-alcoholic fatty liver disease, hyperlipidemia, arteriosclerosis, and thrombosis.

[0042] Therefore, the food composition of this embodiment can be described as a food composition for improving sugar preference, a food composition for restoring sugar preference, a food composition for preventing or ameliorating diabetes, a food composition for preventing or ameliorating obesity, a food composition for preventing or ameliorating irritable bowel syndrome, a food composition for preventing or ameliorating bulimia, a food composition for preventing or ameliorating anorexia nervosa, a food composition for preventing or ameliorating depression, a food composition for preventing or ameliorating hypertension, a food composition for preventing or ameliorating non-alcoholic fatty liver disease, a food composition for preventing or ameliorating hyperlipidemia, a food composition for preventing or ameliorating arteriosclerosis, a food composition for preventing or ameliorating thrombosis, etc.

[0043] The food composition of this embodiment may be used to ingest 0.1 mg / kg to 1 g / kg body weight, for example, 0.5 to 100 mg / kg body weight, for example, 0.5 to 50 mg / kg body weight, for example, 0.5 to 20 mg / kg body weight of the active ingredient (lactic acid bacteria or bifidobacteria) per day. Furthermore, the food composition may be used to ingest once a day or in divided doses about 2 to 4 times a day.

[0044] The food composition of the present embodiment may be in the form of, for example, a supplement, a drink, a solid, semi-solid or gel food, any cooked food, etc. Examples of the form of the supplement include capsules.

[0045] Examples of the form of the supplement include powder, granules, tablets, capsules, etc. Examples of the beverage include coffee, tea, black tea, sports drinks, fruit and vegetable drinks, carbonated drinks, etc.

[0046] [Other Embodiments] In one embodiment, the present invention provides a method for preventing or treating lifestyle-related diseases, which comprises the step of administering an effective amount of lactic acid bacteria or bifidobacteria to a patient.

[0047] In one embodiment, the present invention provides a lactic acid bacterium or a bifidobacterium for use in the prevention or treatment of lifestyle-related diseases.

[0048] In one embodiment, the present invention provides the application of lactic acid bacteria or bifidobacteria in the production of preventive or therapeutic drugs for lifestyle-related diseases.

[0049] In each of these embodiments, the lactic acid bacteria, bifidobacteria, and lifestyle-related diseases are the same as those described above.

[0050] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples.

[0051] [Methods] (Mice) C57BL / 6 (B6) WT mice and ICR mice were obtained from CLEA Japan and Sankyo Labo Service. Germ-free (GF) mice (B6 and ICR) were purchased from Sankyo Labo Service and maintained under GF conditions.

[0052] Ahr-floxed mice (Ahr fl/fl :JAX:006203), Villin CreERT2 Mouse (JAX: 020282), Nr1h4-deficient mouse (JAX: 004144), Cck Cre Mice (JAX:012706), TRAP2 mice (JAX:030323), Ail4 mice (JAX:007914), and Trpm5-KO mice were obtained from The Jackson Laboratory. Ffar2-KO, Ffar3-KO, and Ffar3-floxed mice (Ffar3 fl/fl ) were provided by Dr. I. Kimura (Kyoto University). Gpbar1-KO mice were provided by Dr. Sasaki (University of Tokyo). MyD88-KO mice were obtained from Oriental Bioservices.

[0053] The following double transgenic mouse strains were generated in-house: Cck Cre tdTomato reporter mouse (Cck Cre ×Ai14), CCK + EEC-specific Ffar3-KO mice (Ffar3 EEC-KO :Cck cre ×Far3 fl/fl ), TRAP2 × Ail4 mice, Villin + Epithelial cell-specific Ahr-KO mouse (Villin CreERT2 ×Ahrfl/fl All mice were maintained under standard-feedback conditions with a 12-hour light / 12-hour dark cycle (8:00 AM to 8:00 PM) and free access to a standard control diet (CE2, CLEA Japan), a high-fat diet (HFD) (D12492, Research Diets), or a sucrose-deficient modified HFD (mHFD, Research Diets). Unless otherwise indicated, the facility was maintained at an ambient temperature of 20-23°C and humidity of 40-60%.

[0054] All experiments were approved by the Animal Care and Use Committee (Keio University) and were performed in accordance with institutional guidelines.

[0055] (Human fecal sample) A healthy non-obese volunteer (Japanese, male, 49 years old, body mass index (BMI) = 22.1 kg / m) 2 ) human stool samples were obtained with informed consent (Keio University Ethics Committee, approval number #20140211). Human stool samples were either immediately frozen at −80°C or suspended in a four-fold volume (w / v) of phosphate-buffered saline (PBS) + 20% glycerol solution, flash-frozen in liquid nitrogen, and then stored at −80°C until use.

[0056] (Two-bottle preference test) Mice were housed in test cages (Lick analysis choice preference experimental system LKP2, Melquest) with one mouse per cage and free access to water and food. Humidity and room temperature significantly affect water intake, so they were strictly controlled (22°C ± 1°C, humidity 50% ± 5%).

[0057] Mice were allowed access to two drinking bottles and maintained in cages for 3 days. Before the start of the study, both bottles were filled with water, and the number of times each mouse licked each bottle per day was recorded over 3-5 days. The percentage of licks from each bottle relative to the total number of licks from both bottles was calculated.

[0058] Under SPF conditions, when both bottles contained water, mice licked both bottles equally (40%-60%), and mice that showed a strong preference for either bottle were excluded from the analysis.

[0059] In the two-bottle preference test, mice were allowed to freely choose between a 600 mM glucose solution and a 30 mM acesulfame potassium (AceK) solution for 3 days.

[0060] To evaluate the possible contribution of gut microbiota to sugar preference, mice were orally administered broad-spectrum antibiotics (6.7 g / L ampicillin [A], 6.7 g / L neomycin [N], 3.3 g / L vancomycin [V], and 6.7 g / L metronidazole [M]) three times a week for three weeks (500 μL per mouse). As a control, mice were orally administered the same volume of distilled water. The sweetener bottle was placed during the mouse's active period (8:00 PM to 8:00 AM), and both bottles were filled with water for the rest of the time. The positions of the glucose and AceK bottles were swapped daily. The number of licks of each sweetener bottle was counted, and a preference index was calculated to determine the percentage of licks of the glucose bottle.

[0061] SPF, GF, and exGF mice were housed in sterile isolators (maximum five cages per isolator, one mouse per cage) with free access to water and food. After two weeks of acclimation, mice were given access to two drinking bottles. Hereinafter, the bottle positions are referred to as "left" and "right" from the perspective of the mouse facing the spout. Before the study began, water was placed in the two bottles, one on the left and one on the right, and the daily intake of each bottle by the mice was measured over two days. The percentage of water intake from the left and right bottles relative to the total intake was calculated. In normal mice, the selection rate for each bottle was 40% to 60%. Mice that deviated from this ratio were excluded from the analysis.

[0062] In the two-bottle preference test, mice were allowed to freely choose between a 600 mM glucose solution and a 30 mM AceK solution for three days. The positions of the glucose bottle and the AceK bottle were swapped daily. The daily fluid intake from each bottle was measured, and the rate of glucose solution consumption relative to total consumption was calculated. All in vivo experiments involved mice aged 7-9 weeks at the start of the experiment.

[0063] (Catheterization Surgery) Catheters were surgically implanted into the duodenum-jejunum and ileum of 8-week-old male B6 WT mice. Mice were anesthetized with isoflurane (1-3% in oxygen), and the skin on the abdomen and back was shaved and the body surface was disinfected with 70% ethanol. A small incision was made on the back of the neck, and a midline abdominal incision was made. The entire gastrointestinal tract was exposed through the midline incision.

[0064] A small hole was made in the stomach approximately 0.5 cm from the pylorus and 5 cm from the cecum with a 23G needle. A polyurethane catheter (BTPU-014, Prime Biosciences) was implanted into the gastrointestinal tract through the hole and held in place with Tissue Adhesive (1469SB, 3M).

[0065] The opposite end of the catheter was connected to a dosing connector (VABM2JB / 25R25, Prime Biosciences) placed outside the body through a small incision at the back of the neck via the peritoneum. The catheter was flushed with sterile PBS three times a week to prevent blockage. Mice were allowed to recover from surgery for at least one week before starting the experiment.

[0066] (Jejunal and Ileal Infusion) The catheters were connected to a syringe controlled by a tube (01631-05, Eastside Med) and an infusion pump (MELQUEST, 703007). Catheter infusion was performed every 10 licks of the bottle under the control of the LKP2-ANPC system (MELQUEST) at a rate of 0.180 mL / min until an infusion volume of 0.03 mL was reached. To prevent blockage, the catheters were flushed with sterile PBS before and after the experiment.

[0067] (Two-Flavor-Nutrient Conditioning Test) After 3 weeks of broad-spectrum antibiotic administration (Abx, AMNV), 8-week-old male B6 mice underwent duodenal catheterization and duodenal-jejunal sweetener infusion conditioning. Prior to flavor conditioning, mice were tested for preference for two flavors without duodenal-jejunal sweetener infusion (days 1 and 2).

[0068] Conditioning training was conducted on alternate days with one of two flavors: one flavor (grape; grape solution was 0.39 g / L Kool-Aid Unsweetened Grape in 1 mM AceK in Milli-Q water, Kraft Heinz Company) associated with an enteral infusion of glucose (days 3 and 5), and the other flavor (cherry; cherry solution was 0.39 g / L Kool-Aid Unsweetened Cherry in 1 mM AceK in Milli-Q water, Kraft Heinz Company) associated with an enteral infusion of AceK (days 4 and 6).

[0069] Flavor preference was assessed after conditioning training in a two-bottle preference test without intragastric infusion (days 7 and 8). The number of licks taken from each bottle was counted, and a preference index was calculated. The preference index was calculated as the percentage of licks taken from the grape bottle relative to the total number of licks taken.

[0070] Eight-week-old male B6 mice underwent duodenal and ileal catheterization. After 2 weeks of recovery, mice were given a choice between grape and cherry without any intestinal infusion (pre-injection: days 1 and 2).

[0071] During conditioning training, on alternate days, one of the two flavors (grape) was associated with a duodenal infusion of glucose (days 3 and 5), and the other flavor (cherry) was associated with an ileal infusion of glucose (days 4 and 6). Flavor preference was assessed after conditioning training in a two-bottle preference test without intraluminal infusion (days 7 and 8). The number of licks taken from each bottle was counted, and a preference index was calculated. The preference index was calculated as the percentage of licks taken from the grape bottle relative to the total number of licks taken.

[0072] (Sugar 2 Preference Test Using Drosophila melanogaster) Drosophila melanogaster Canton-S strain was maintained on a standard diet at 25°C, 50-60% relative humidity, and a 12-hour light / 12-hour dark cycle (light period, 9:00 AM to 9:00 PM).

[0073] Newly developed male flies were incubated in CO2 Flies were collected under anesthesia with acetaminophen and placed in plastic vials containing diet with or without antibiotics. Antibiotic diet was prepared as previously described by adding rifampicin (Fujifilm Wako Pure Chemical Industries, Ltd., #189-01001) dissolved in dimethyl sulfoxide to a final concentration of 200 μg / mL, tetracycline (Fujifilm Wako Pure Chemical Industries, Ltd., #209-16561) dissolved in water to a final concentration of 50 μg / mL, and ampicillin (Fujifilm Wako Pure Chemical Industries, Ltd., #016-23301) dissolved in water to a final concentration of 500 μg / mL. Flies were housed in a vial with 15 individuals for 7–9 days.

[0074] The two-choice test was performed as follows: a mixture of 1% agarose, 50 mM D-glucose (Fujifilm Wako Pure Chemical Industries, #049-31165), and 300 μg / mL Brilliant Blue FCF (Fujifilm Wako Pure Chemical Industries, #027-12842) and a mixture of 1% agarose, 200 mM L-glucose (Tokyo Chemical Industry, #G226), and 300 μg / mL sulforhodamine B (Sigma-Aldrich, #S1402) were prepared as colored sugar substrates.

[0075] Round-bottom 96-well Terasaki plates were alternately filled with colored substrates (approximately 20 μL per well). Flies were anesthetized on ice for 1 minute and then introduced into the plates. The plates were placed in the dark at 25°C for 2 hours, and the flies were allowed to feed ad libitum. After the test, the plates were frozen and dead flies were analyzed under a stereomicroscope. The number of flies that ingested each sugar substrate was counted based on the abdominal color. The preference index was calculated using the following formula: Preference index = [(number of flies stained blue) - (number of flies stained red)] / [(number of flies stained blue) + (number of flies stained red)]

[0076] (Vagotomy) Bilateral (VGx), unilateral (left [LVx] or right [RVx]) subdiaphragmatic, common hepatic branch of the left vagus nerve (cHVx), proper hepatic branch (pHVx), and gastroduodenal branch vagotomy (GDVx) were performed as previously reported.

[0077] Male mice were anesthetized with a combination of medetomidine, midazolam, and butorphanol and underwent a midline incision to expose the upper abdominal organs. The bilateral subdiaphragmatic trunks of the vagus nerve along the esophagus were exposed and transected. In the sham-operated group, these trunks were exposed but not transected.

[0078] Proper hepatic branch transection (pHVx) or gastroduodenal branch transection (GDVx) was performed for the first time in this study. Under anesthesia, the ventral subdiaphragmatic vagus trunk was exposed as described above. Because the proper hepatic branch and gastroduodenal branch branch off from the common hepatic branch of the vagus nerve to form a neurovascular bundle, these branches were selectively ligated with silk sutures and severed with microscissors.

[0079] (TRAP induction) First, 4-hydroxytamoxifen (4-OHT, Sigma) was dissolved in ethanol at 37°C for 15 minutes with shaking to a concentration of 20 mg / mL. The dissolved 4-OHT was then stored at -20°C for up to several weeks or used immediately.

[0080] The dissolved 4-OHT was mixed with corn oil (Fujifilm Wako Pure Chemical Industries, Ltd.) to a concentration of 10 mg / mL, shaken at room temperature for 15 minutes, and then the ethanol was evaporated by vacuum centrifugation. The final 10 mg / mL 4-OHT solution was injected intraperitoneally into mice at a dose of 50 mg / kg on the same day.

[0081] To induce TRAP response to sweeteners, TRAP2 and TRAP2xAil4 mice were fasted for 3 hours before injection. After intraperitoneal injection of 4-OHT, the mice were given 600 mM glucose or 30 mM AceK solution ad libitum and then fasted for another 6 hours. After that, the mice were returned to their home cages and given control chow and water ad libitum.

[0082] (Detection of Fos activation) Sweetener-induced TRAP2 × Ail4 mice were perfused with 4% PFA, and the nodose ganglia (NG) were isolated. The NG was post-fixed overnight at 4°C, placed in 20% sucrose at 4°C for 16 hours or more, and then frozen on dry ice in OCT compound (Sakura Finetech Japan).

[0083] Longitudinal sections (8 μm) of the NG were cut at 48 μm intervals using a precision cryostat (Leica). After DAPI staining, fluorescent images were acquired using an LSM710 confocal laser scanning microscope (Carl Zeiss), and tdTomato-positive neurons in the NG were counted.

[0084] (NG injection of AAV9) AAV9.U6.Scramble.CMV.EGFP.pA (AAV9-ShCont), AAV9.U6.ShGlp1r.CMV.EGFP.pA (AAV9-ShGlp1r), AAV9.Camk2a.FLEX-T2A-EGFP-WPRE.bGHpA (AAV9-FLEX-EGFP), and AAV9.Camk2a.FLEX-T2A-DTA-EGFP-WPRE.bGHpA (AAV9-FLEX-DTA) were purchased from Vector Builder Japan. Immediately before the experiment, virus aliquots were diluted to 1 × 10 in PBS containing 0.1% FastGreen (Sigma, F7262). 13 Diluted to a titer of CG / mL.

[0085] Mice were anesthetized with isoflurane (1-3% in oxygen), and the abdominal and back skin was shaved and the body surface was disinfected with 70% ethanol. The vagus nerve was separated from the carotid artery using microscissors (Natsume Seisakusho) and Dumont forceps (MA-45, Dumont), and the NG was made accessible under a stereomicroscope.

[0086] The virus aliquots were loaded into NANOFIL microliter syringes (World Precision Instruments), and 500 nL of each AAV9 aliquot was injected bilaterally into the NG using a microinjector system (MDS-1, Narishige).

[0087] (Vagus nerve silencing experiments) To inject AAV9-FLEX-EGFP and AAV9-FLEX-DTA into the NG, 6-week-old male TRAP2 mice were anesthetized with 1% to 2% isoflurane. Mice were allowed to recover for at least 2 weeks before in vivo experiments to ensure animal health and allow AAV infection before Cre recombination. One week after glucose-induced TRAP2 induction, mice underwent a two-bottle preference test. After the test, the effects of AAV9 infection and CRE recombination in the NG of glucose-induced TRAP2 mice were evaluated by observing the fluorescently labeled protein EGFP in the NG.

[0088] (Ablation of Glucose-Activated Neurons in the NG) TRAP2 mice were injected with AAV9 expressing FLEX DTA into both NGs and then stimulated with intragastric glucose injection. After 2 weeks of recovery, mice in which glucose-responsive neurons in the NG were depleted by 4-OHT injection (glucose-NG-depleted mice) were given a choice between glucose and AceK 1 week after 4-OHT injection (n = 5 per group). The number of licks from each bottle was counted, and the PI within the test box was calculated by dividing the number of licks from the glucose bottle by the total number of licks. P values ​​were determined using an unpaired Student's t-test.

[0089] (Gnotobiotic Mice) Jejunal contents from various mice or feces from healthy human donors were collected and suspended in an equal volume (w / v) of PBS containing 40% glycerol, flash-frozen, and stored at -80°C until use. Frozen stocks were thawed, suspended in 5 volumes of PBS, and passed through a 100 μm cell strainer. GF mice were orally inoculated with 200 μL of the suspension using a sterile stainless steel feeding needle. The phenotype of colonic immune cells was analyzed after a 3-week colonization period.

[0090] (Fecal sample collection and bacterial DNA isolation) Peripheral duodenal samples were collected sequentially from each mouse. Mice were housed in separate cages for this experiment. Bacterial DNA was isolated by enzymatic lysis using lysozyme and achromopeptidase. DNA samples were then purified by treating with RNase A and then precipitating with 20% polyethylene glycol solution (PEG 6000 in 2.5 M sodium chloride). DNA was then pelleted by centrifugation, rinsed with 75% ethanol, and dissolved in Tris-EDTA buffer.

[0091] (Bacterial Culture) Frozen stocks of duodenal-jejunal contents from mice administered metronidazole and neomycin for 3 weeks were diluted and anaerobically cultured on Gifu Anaerobic Medium (GAM) (Shimadzu Diagnostics), glucose blood liver medium (BL) (Shimadzu Diagnostics), agar medium, and de Man-Rogosa-Sharpe (MRS) (Merck Millipore) agar medium for 48 hours in a chamber (Concept 400, Baker) gas-substituted with a mixture of 80% nitrogen, 10% hydrogen, and 10% carbon dioxide.

[0092] The 16S rRNA gene sequences of the isolates were determined using sequencing primers (27F, 518F, 800R, 1492R). Sequences were aligned using Clustal Omega. 16S rRNA sequences of closely related species were aligned using PyNast, and a neighbor-joining phylogenetic tree was generated using MEGA 6.0 software.

[0093] (In vitro bacterial growth assay) To estimate the utilization characteristics of Bifidobacterium pseudolongum (Bp) for various carbohydrates, it was cultured in sugar-free MRS broth (Alpha Biosciences) containing monosaccharides (glucose, galactose, mannose, fructose, lactose, and sucrose). After sterilization using a 0.22 μm filter (Merck), simple sugars and oligosaccharides were added to the sugar-free MRS broth to a final concentration of 10 g / L. Bp was inoculated into the prepared MRS medium at 1% (v / v) and anaerobically cultured at 37°C for 48 hours. After 48 hours, turbidity was measured at OD600. Fermentation samples were centrifuged at 10,000 × g for 10 minutes and used for SCFA measurement.

[0094] Quantification of fecal microbiota by qPCR. Quantification of Bp and Enterococcus gallinarum (Eg) was performed using SYBR Premix EX Taq II (Takara Bio) and Thermal Cycler Dice Real Time System II (Takara Bio). The primer sets were as follows: Bp: forward 5'-TCATGGCTCAGGATGAACGC-3' (SEQ ID NO: 7) and reverse 5'-CAGGAGCTATTCCGTGCAT-3' (SEQ ID NO: 8). Eg: forward 5'-TTACTTGCTGATTTTGATTCG-3' (SEQ ID NO: 9) and reverse 5'-TGAATTCTTCTTTGAAATCAG-3' (SEQ ID NO: 10).

[0095] (Measurement of SCFA by HPLC) Jejunal contents were diluted with PBS (1:10, w / v) and vortexed for 2 minutes. The sample was centrifuged at 15,000 × g for 10 minutes, and the supernatant was filtered through a 0.45 μm filter. SCFA were measured by high-performance liquid chromatography (Prominence, Shimadzu) according to the manufacturer's protocol using a post-column reaction equipped with a detector (CDD-10A, Shimadzu), two tandem columns, and a guard column (Shim-pack SCR-102, Shimadzu). Glucose concentration was measured by hexokinase reaction using an ultraviolet absorption spectrophotometer at 340 nm according to the manufacturer's instructions.

[0096] (Measurement of GLP1, insulin, and leptin in serum) Commercially available enzyme-linked immunosorbent assay kits were used to measure serum insulin (Mercodia), serum LPS (Cloudclone), serum leptin (R&D Systems), and serum GLP1 (Merck Millipore).

[0097] (Sequencing and processing of bacterial 16S rRNA genes in luminal content DNA) The hypervariable V3-V4 region of the 16S rRNA gene was amplified using Ex Taq Hot Start (Takara Bio) and then purified using AMPure XP (Beckman Coulter). Approximately equal amounts of each amplified DNA were then sequenced using MiSeq Reagent Kit V3 (600 cycles) on a MiSeq sequencer (Illumina) according to the manufacturer's instructions. Sequences were analyzed using the QIIME2 software package (version 2021.8).

[0098] Forward and reverse reads were combined, denoised, and checked for chimeras using the QIIME2 command. Classification was determined using silva-138-99-nb-classifier.qza.

[0099] Statistical analysis and PCoA plot generation for alpha diversity metrics and PCoA plot generation for beta diversity metrics were also performed using the QIIME2 command. Sampling depth (-p-sampling-depth) was set to the minimum remaining read counts among samples.

[0100] (Whole genome sequencing of Bp and Bpc) DNA was extracted from Bp, Eg, Lf, Lh, Li, Lj, Lv, and Bpc using a Genomic-tip 20G kit (Qiagen). The concentration of the DNA solution was measured using a QuantiFluor dsDNA System and a Quantus Fluorometer (Promega). Electrophoresis was performed using a 5200 Fragment Analyzer System and an Agilent HS Genomic DNA 50kb Kit (Agilent Technologies) to confirm the quality of the DNA. Low molecular weight molecules were removed using a Short Read Eliminator XS (PacBio). DNA was fragmented into 10-20 kbp fragments using g-TUBE (Covaris). The manual "Procedure & Checklist - Preparing HiFi Libraries from Low DNA Input Using SMRTbell" was used. (R) Based on the "Express Template Prep Kit 2.0," a DNA library was prepared using SMRTbell Express Template Prep Kit 2.0 (PacBio), a polymerase complex was formed with the library using Binding kit 2.2 (PacBio), and sequencing was performed using Sequel IIe (PacBio).

[0101] Subreads were generated after removing adapter sequences from the sequencing data using SMRT Link (v. 11.0.0.146107). HiFi reads were generated by removing consensus sequences obtained from the alignment of subreads with an average CCS quality score of less than 20 per read. HiFi reads shorter than 1,000 bases were removed using Filtrong (v. 0.2.1). HiFi reads longer than 1,000 bases were assembled using Flye (v. 2.9.1-b1780) under default conditions. The assembled contig graph was verified using Bandage (v. 0.8.1). The completeness of the assembled genome data was verified using CheckM (v. 1.2.2). Gene predictions were performed from the assembled sequences using Prokka (v. 1.14.5).

[0102] The nucleotide sequences of the entire genome of Bifidobacterium pseudolongum (Bp) are shown in SEQ ID NOs: 1 and 2. The nucleotide sequence of the entire genome of Bifidobacterium pseudocatenulatum (Bpc) is shown in SEQ ID NO: 3. The nucleotide sequences of the entire genome of Enterococcus gallinarum (Eg) are shown in SEQ ID NOs: 4 to 6.

[0103] (Shotgun genome sequencing of feces from mHFD-fed mice) Fecal samples were freeze-dried using a VD-250R freeze dryer (Taitec) and pulverized for 2 minutes at 1,500 rpm using a Multi-Bead Shocker (Yasui Kikai). Lysis Solution F (Nippon Gene) was then added to the pulverized sample. After 10 minutes at 65°C, the solution was centrifuged at 12,000 × g for 2 minutes, and DNA was extracted from the supernatant using a DNA extraction kit (ZEESAN). DNA concentration was measured using a Synergy LX (Agilent Technologies) and a QuantiFluor dsDNA System (Promega). DNA libraries were prepared according to the "MGIEasy FS DNA Library Prep Set" (MGI Tech) manual. The enzymatic reaction time was 8 minutes. Adapters from the MGIE Easy DNA Adapters-96 (Plate) kit (MGIE Tech) were also used. The concentration of the library solution was measured using a Qubit 3.0 Fluorometer and a dsDNA HS Assay Kit (Thermo Fisher Scientific). The quality of the prepared library was confirmed using an Agilent 2100 Bioanalyzer and High Sensitivity DNA Kits (Agilent Technologies). Circularized DNA was prepared from the library using the MGIE Easy Circularization Kit (MGIE Tech) according to the manufacturer's instructions. DNBs were prepared using the DNBSEQ-G400RS High-Throughput Sequencing Kit (MGI Tech) as described in the manual. For data analysis, sequencing reads were first trimmed using Atria v3.2.2 to remove adapters and low-quality bases. Host genome sequences were removed using KneadData v0.12.0. Samples that passed quality assurance were taxonomically profiled using Kraken v2.1.2 and Bracken v2.8, and outputs were merged to generate species-level assignments. To identify the functional potential of the microbiome, MetaPhlAn 3.0 data were run through HUMAnN 3.0.

[0104] (Immunohistochemistry) Anti-mouse Ffar3 antibody (ab236654, Abcam) was conjugated with biotin using the Ab-10 Rapid Biotin Labeling Kit (Dojindo Laboratories). Mice were perfused with 4% PFA, and the small intestine and NG were collected. Samples were cryoprotected in 20% sucrose solution for 24 hours and stored in OCT compound. For immunohistochemistry, antigens were blocked with Block Ace. Primary antibody reactions were performed overnight at 4°C (dilution ratio: FFAR3 [1 / 200], proCCK [1 / 200], GLP1 [1 / 500], GLP1R [1 / 200]). After washing with PBS, the sections were incubated with Alexa Fluor 488- or Alexa Fluor 647-labeled secondary antibodies (1 / 400) for 2 hours at room temperature. Tissue samples were observed under an LSM710 confocal laser scanning microscope (Carl Zeiss).

[0105] (Scanning Electron Microscopy) A 2 cm section of dissected intestine was cut open, washed with PBS, and fixed overnight at 4°C in 2% paraformaldehyde / 2% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). The sample was fixed with 2% osmium tetroxide in 0.1 M phosphate buffer for 2 hours at 4°C and then dehydrated through a graded ethanol wash process for scanning electron microscopy. The sample was transferred to tert-butyl alcohol three times for 30 minutes each and frozen at 4°C. After drying, a thin film of osmium (35 nm) was coated using an osmium plasma coater (NL-OPC80NS, Japan Laser & Electronics). The sample was imaged using a scanning electron microscope (JSM-7500F, JEOL) at an accelerating voltage of 3.0 kV and photographed with a digital camera.

[0106] (STC-1 Cell Culture) STC-1, a mouse EEC line, was purchased from ATCC. STC-1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM, Nacalai Tesque) containing 10% (v / v) fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin solution (PS, Nacalai Tesque). Silencer TMSelect Pre-Designed siFfar2, siFfar3, and a negative control were purchased from Thermo Fisher Scientific. SiRNA (100 nM) was transfected using Lipofectamine RNAiMAX (Thermo Fisher Scientific) according to the manufacturer's instructions.

[0107] (Quantitative PCR by reverse transcription) RNA was isolated and purified from NG and cells using the RNeasy Mini Kit (Qiagen). Reverse transcription was performed using the iScript cDNA Synthesis Kit (Bio-Rad). Real-time PCR amplification was performed using the Thermal Cycler Dice Real Time System (Takara Bio). Gene expression levels were normalized to 18S ribosomal mRNA.

[0108] (Intracellular Ca 2+ Measurement of concentration) STC-1 cells (10,000 cells) were seeded in a 96-well plate. After 24 hours of culture, the medium was replaced with glucose-depleted DMEM, and GAM or bacterial culture supernatant (BCS, diluted 1:10) was added and cultured for an additional 6 hours. STC-1 cells were washed twice with assay buffer (HBSS 1x, 20 mM HEPES [pH 7.4]) and loaded with Fluo-4 AM (Dojindo Laboratories) according to the manufacturer's protocol (Invitrogen), followed by stimulation with 1 mM glucose. Fluo-4 fluorescence was measured 2 minutes after glucose addition using Infinite 200 PRO (Tecan).

[0109] (GLP-1 secretion in STC1 cells) For the GLP-1 secretion assay, STC-1 (10,000 cells) were cultured overnight in a 96-well plate. On the day of treatment, the cells were treated with glucose-deficient DMEM containing GAM or BCS (dilution ratio 1:10) for 6 hours, followed by glucose stimulation (1 mM) for 2 hours. The cell supernatant was then collected and the GLP-1 concentration was measured.

[0110] (Whole-cell patch clamp recording) STC1 cells were seeded on uncoated coverslips and cultured in glucose-containing medium at 37°C in a humidified incubator. 48 hours after seeding, the medium was replaced with fresh glucose-free medium containing GAM or Bp supernatant and cultured for an additional 24 hours. Whole-cell current clamp recording was performed in 140 mM NaCl, 5 mM KCl, 2 mM CaCl. 2 , 2 mM MgCl 2 The experiments were performed at room temperature in a bath solution containing 10 mM KCl, 10 mM D-glucose, and 10 mM HEPES (adjusted to pH 7.40 with NaOH). The membrane potential was recorded using a Multiclamp 700B amplifier (Molecular Devices) and digitized using a Digidata 1550B digitizer (Molecular Devices). Cells were maintained under whole-cell conditions for approximately 5 min, after which the intracellular solution was completely replaced with a pipette solution containing 140 mM KCl, 5 mM ethylene glycol tetraacetic acid (EGTA), and 10 mM HEPES. The pipette resistance was 4 ± 1 MΩ. The resting membrane potential was artificially maintained at approximately -70 mV by current injection. 500-ms step pulses were applied every 3 s, with the stimulus amplitude increasing by 5 pA per step. Data were acquired using pCLAMP11 (Axon Instruments) and statistically analyzed using Origin 2021 pro (Mann-Whitney U test).

[0111] (Oral Bp treatment) 30 minutes before the behavioral test, GAM or Bp (1 × 10 13 Mice were administered Bp daily, starting 12 hours before the two-bottle preference test and continuing throughout the behavioral testing period.

[0112] (In vivo treatment with T1R2 / 3 agonists, SGLT1 inhibitors, CCKA receptor antagonists, and GLP1-R antagonists) In studies using sweet-insensitive mice, a T1R2 / 3 agonist (gurmarin, Fujifilm Wako Pure Chemical Industries) was dissolved in each sweetener solution to a concentration of 30 μg / mL. For the two-bottle preference test, a sweetener solution containing gurmarin was used. For the SGLT1 inhibition test, an SGLT1 inhibitor (phlorizin) was purchased from Tokyo Chemical Industry Co., Ltd. Phlorizin was administered subcutaneously at 400 mg / kg twice daily. Phlorizin was administered 12 hours before the two-bottle preference test and daily throughout the two-bottle preference test. For the CCK blockade test, a CCKA receptor antagonist (devazepide: Dev) was purchased from Sigma-Aldrich. Devazepide was administered intraperitoneally at 300 μg / kg body weight 30 minutes before the two-bottle preference test and daily throughout the two-bottle preference test. For the GLP1 blockade test, a GLP1 receptor antagonist (Exendin (9-39): Ex-3) was purchased from Sigma-Aldrich. Ex-3 was administered intraperitoneally at 600 nmol / kg body weight 30 minutes before the two-bottle preference test every day.

[0113] (Chronic two-bottle preference test in mice) Eight-week-old male WT mice were fed a sucrose-deficient mHFD for 4 weeks and then divided into four treatment groups (n = 6 per group) that received an HFD for an additional 4 weeks. 1) Mice fed on mHFD were orally administered GAM daily and given free access to glucose / glucose solution (Bp-untreated GG group). 2) Mice fed on mHFD were orally administered GAM daily and given free access to glucose / AceK solution (Bp-untreated GA group). 3) Mice fed on mHFD were orally administered Bp daily and given free access to glucose / glucose solution (Bp-treated GG group). 4) Mice fed on mHFD were orally administered Bp daily and given free access to glucose / AceK solution (Bp-treated GA group).

[0114] (Statistics) All values ​​are expressed as mean ± SEM. Statistical analysis was performed using an unpaired two-tailed Student's t-test or one-way ANOVA with Tukey's post-hoc test for multiple comparisons. P < 0.05 was considered statistically significant. No statistical methods were used to determine sample size in advance.

[0115] [Experimental Example 1] (Examination of the role of intestinal flora in SP 1) To investigate the role of intestinal flora in sugar preference (SP), the level of SP was examined using germ-free (GF) C57BL / 6 (B6) male mice.

[0116] Figure 1 shows a schematic diagram outlining the experiment and a graph showing the results. In Figure 1, "Glu" means glucose. Under specific pathogen-free (SPF) conditions, mice showed SP in a two-bottle preference test for glucose (600 mM) and the artificial sweetener acesulfame potassium (AceK) (30 mM), which are iso-sweetened.

[0117] In contrast, GF mice failed to acquire SP. Furthermore, SP was restored in GF mice (exGF) that were transplanted with feces from age-matched SPF B6 mice fed a normal diet (ND).

[0118] [Experimental Example 2] (Study on the role of intestinal microbiota in SP 2) The intestinal microbiota of 8-week-old SPF B6 mice was depleted using an oral antibiotic cocktail (ampicillin [A], metronidazole [M], neomycin [N], vancomycin [V], hereinafter sometimes referred to as "AMNV"), and SP was measured.

[0119] Figure 2 shows a schematic diagram outlining the experiment and a graph showing the results. In Figure 2, "Abx" means antibiotic. Two weeks after AMNV administration, the mice lost their SP.

[0120] [Experimental Example 3] (Examination of the role of intestinal flora in SP 3) In order to examine the role of human intestinal flora in SP, GF mice (GF mice) were transplanted with feces from a healthy human (derived from a 49-year-old Japanese male with an obesity index of 22.1). hu The SP of mice (GF mice) was examined. Figure 3 is a graph showing the results. In Figure 3, "Abx" means antibiotics. hu Mice acquired SP, which was abolished by AMNV treatment.

[0121] [Experimental Example 4] (Study on other host animal species) To investigate whether the establishment of intestinal microbiota-dependent SP is observed in other host animal species, two sugar preference assays (D-glucose or L-glucose) were performed using fruit flies (Drosophila melanogaster).

[0122] Figure 4 shows a schematic diagram outlining the experiment and a graph illustrating the results. In Figure 4, "Abx" stands for antibiotic. Flies reared under normal conditions preferred the nutritious D-glucose over the less nutritious L-glucose, but flies treated with an antibiotic cocktail (rifampicin, tetracycline, and ampicillin) showed significantly less preference for D-glucose.

[0123] Notably, antibiotic treatment did not alter the flies' preference for each sugar over plain agarose. These results suggest that the role of the microbiota in the SP is evolutionarily conserved.

[0124] [Experimental Example 5] (Investigation of the contribution of sweet taste sensors to SP) To exclude the possibility of contribution of sweet taste sensors expressed in mouse taste buds and enteroendocrine cells (EECs), the sweet taste sensing function was inhibited using gurmarin, a T1R2 / T1R3 inhibitor.

[0125] The results are shown in Figure 5. In Figure 5, "Glu" means glucose, and "Abx" means antibiotic. T1R2 / T1R3 inhibition did not affect SP under SPF conditions, but AMNV treatment resulted in a loss of SP.

[0126] [Experimental Example 6] (Investigation of the Contribution of Intestinal Microbiota to SP) Under SPF conditions, flavor-nutrient conditioning was performed between oral ingestion of cherry flavor coupled with intragastric water infusion (water reward) and oral ingestion of grape flavor coupled with intragastric glucose infusion (glucose reward), and SP was measured.

[0127] Figure 6 shows a schematic diagram outlining the experiment and a graph showing the results. The results demonstrated that flavor-nutrition conditioning was established. Furthermore, this SP disappeared upon AMNV treatment. Based on these results, we concluded that the intestinal microflora is necessary for the establishment of the host's SP.

[0128] [Experimental Example 7] (Study of SP-specific site) SP was measured using vagotomized mice. The results suggested that a glucose sensor for SP mediated by microbiota exists in the upper small intestine (uSI).

[0129] Under SPF conditions, flavor and nutrient conditioning tests were performed between oral administration of grape flavor and infusion of 10% glucose-containing water into the uSI, and oral administration of cherry flavor and infusion of 10% glucose-containing water into the lower small intestine (loSI). Before conditioning, SPF mice showed an equal preference for grape-flavored water and cherry-flavored water, but after conditioning, they began to prefer grape flavor.

[0130] We investigated the expression of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP1) in the uSI of SPF mice. Both CCK and GLP1 markers were expressed in EECs scattered throughout the uSI, and GLP1 was also expressed in EECs. + EEC is CCK + It overlapped in part with the EEC.

[0131] To investigate the functional role of GLP1 in the acquisition of microbiota-mediated SPF, we administered a CCK inhibitor (devazepide [Dev]) or a GLP1-R inhibitor (Exendin(9-39) [Ex-3]) and measured SP. SP was eliminated by Ex-3 treatment but not by Dev treatment.

[0132] Injection of AAV9-ShGLP1r:EGFP into bilateral NG to inhibit GLP1-R-expressing NG afferents abolished SP under SPF conditions.

[0133] Taken together, these results suggest that the uSI is a specific site of SP via signaling in EECs by an unidentified microbiota in cooperation with the vagal afferent gut-brain axis, which expresses SGLT1 and GLP1R.

[0134] Experimental Example 8 (Investigation of Microorganisms Causing SP 1) The specific microflora causing SP in the upper small intestine (uSI) was investigated. B6 mice were administered AMNV cocktail, ampicillin (A), metronidazole (M), neomycin (N), vancomycin (V), MN cocktail, or water for 3 weeks, and a two-bottle preference test for glucose and AceK was performed in a test box (n=4 per group). Figure 7 is a graph showing the results. As a result, SP was inhibited in mice treated with V or A, but was maintained in mice treated with M and / or N.

[0135] The SP-specific microbiota was identified based on the sensitivity of SP to specific antibiotics. Jejunal contents from mice treated with both M and N were transplanted into GF mice (GF MN mice). Figure 8 shows the GF MN 8 is a graph showing the results of measuring the SP of mice. MN Mice carried SP.

[0136] FIG. 9 is a schematic diagram illustrating the outline of the experiment and a graph showing the results. MNMouse jejunal contents were cultured under various anaerobic culture conditions. The results of 16S rRNA analysis showed that the following bacteria were present: Bifidobacterium pseudolongum (Bp), Enterococcus gallinarum (Eg), Lactobacillus hominis (Lh), Lactobacillus intestinalis (Li), Lactobacillus johnsonii (Lj), Lactobacillus reuteri (Lr), Lactobacillus vaginalis (Lactobacillus Seven bacterial species were identified, including five lactic acid bacteria (L. vaginalis, Lv).

[0137] Subsequently, seven isolates were independently transplanted into GF mice and subjected to two-bottle preference tests. As a result, all isolates were found to have a tendency to induce SP in GF mice. In particular, Bifidobacterium pseudolongum (Bp) and Enterococcus gallinarum (Eg) had a high SP-inducing ability.

[0138] [Experimental Example 9] (Investigation of the mechanism mediating SP 1) SP was measured using various genetically modified mice lacking the genes for MyD88 (Myd88), Villin-specific AhR (Ahr), GPR41 (Ffar3), GPR43 (Ffar2), TGR5 (Nrfh4), and FXR (Gpbar1).

[0139] The results are shown in a graph in Figure 10. Among these mice, only the GPR41 KO mice lost SP under SPF conditions.

[0140] [Experimental Example 10] (Study on the mechanism mediating SP 2) We investigated whether GPR41 on EEC is necessary for microbiota-mediated SP. EEC-specific GPR41 conditional knockout mice (CCK) cre/+ ×GFP41 fl/fl ) was prepared and the SP was measured.

[0141] Figure 11 is a graph showing the results. cre/+ ×GFP41 fl/fl Mice were control CCK +/+ ×GFP41 fl/fl In contrast to mice, EECs lacked SP, indicating that GPR41 on EECs is required for microbiota-mediated SP.

[0142] [Experimental Example 11] (Investigation of the Mechanism Mediating SP 3) Short-chain fatty acids (SCFA), which are ligands for GPR41, are thought to be produced by microbiota and stimulate EECs to produce GLP1 mainly in the lower small intestine (loSI) and colon. However, it has not yet been clarified whether microbiota that produce SCFA exist in the upper small intestine (uSI).

[0143] To explore this possibility, GF MN Culture supernatants of seven types of bacteria (Bp, Eg, Lh, Li, Lj, Lr, and Lv) isolated from mouse uSI were prepared and their biological effects on STC-1 cells, a mouse EEC cell line, were examined.

[0144] STC-1 cells were treated with Gifu anaerobic medium (GAM) or each bacterial culture supernatant (BCS) for 6 hours, stimulated with or without glucose, and intracellular calcium ion concentration was measured (n = 8 per group). GLP1 secretion was measured after STC-1 cells were treated with GAM or each BCS for 6 hours, followed by treatment with or without glucose for 1 hour.

[0145] 12 is a graph showing the results. As a result, consistent with the acquisition of SP by Bp and Eg, the culture supernatants of Bp and Eg showed a significant increase in intracellular Ca in the presence of glucose compared to the control (GAM). 2+ The five SP-uninduced lactic acid bacteria strains (Lh, Li, Lj, Lr, and Lv) significantly increased intracellular Ca 2+ No increase in concentration or GLP1 production was observed.

[0146] FIG. 13 shows the results of adding the culture supernatant of Bp or Eg to the medium of STC-1 cells treated with siRNA against Ffar3 (si-Ffar3), siRNA against Ffar2 (si-Ffar2), or control siRNA (si-Cont), and measuring the intracellular Ca 2+ The graph shows the results of measuring the concentration and GLP1 production amount (n=8 for each group). As a result, treatment with siRNA against Ffar3 but not Ffar2 increased intracellular Ca 2+ It was revealed that the concentration and production of GLP1 were significantly reduced.

[0147] GPR41 is known as a Gαi-type G protein-coupled receptor (GPCR) that receives SCFA, and signal transduction induces extracellular signal-regulated kinase (ERK) phosphorylation via Gαi association. Figure 14 shows the effect of adding the culture supernatant of Bp or Eg to the culture medium of STC-1 cells in the presence of pertussis toxin (PTX), a Gαi inhibitor, or vehicle (Veh), on the intracellular Ca 2+ The results of measuring the concentration of pertussis toxin (PTX) and the amount of GLP1 produced are shown in Fig. 1 (n=8 for each group). 2+ The increase in concentration and the increase in GLP1 production disappeared.

[0148] To clarify the involvement of metabolites derived from SP-inducing bacteria in electrophysiological function, STC-1 cells were incubated in the culture medium of the SP-inducing bacteria Bp for 24 hours and whole-cell patch clamp recordings were performed. Figure 15 shows the results. As a result, the mean threshold of cells cultured in Bp culture supernatant was significantly lower than that of the control GAM culture. This result indicates that Bp culture supernatant contains unidentified microbial metabolites that enhance the electrical activity of STC-1 cells.

[0149] [Experimental Example 12] (Identification of SP-responsive GPR41 ligand) To identify SP-responsive GPR41 ligands in the upper small intestine (uSI), we searched for intestinal bacterial metabolites that enable the host to acquire SP. We measured the SCFA concentration in the uSI of gnotobiotic mice transplanted with seven types of bacteria (Bp, Eg, Lh, Li, Lj, Lr, and Lv).

[0150] The results are shown in Figure 16. Bp-gnotobiotic mice and Eg-gnotobiotic mice produced significant amounts of acetate, but not propionate or butyrate. Lactobacillus-gnotobiotic mice did not produce any SCFA.

[0151] [Experimental Example 13] (Investigation of Auxotrophy of Bp) In order to clarify the characteristics of bacteria that allow them to survive in uSI, the auxotrophy of Bp, an SP-inducing bacterium, was investigated.

[0152] Figure 17 shows images of the uSI (jejunum) of Bp-gnotobiotic GF mice observed with a scanning electron microscope. As shown in Figure 17, Bp was attached to the luminal contents in the uSI of Bp-gnotobiotic GF mice.

[0153] Fig. 18 is a graph showing the results of examining the ability of Bp to utilize various carbon sources. In Fig. 18, "Glu" represents glucose, "Gal" represents galactose, "Lac" represents lactose, "Mal" represents maltose, "Fru" represents fructose, "Man" represents mannan, and "Sta" represents starch.

[0154] In vitro, Bp growth was significant in the presence of glucose, galactose, sucrose, lactose, and maltose, including SGLT1 ligands (glucose or galactose), but no Bp growth was observed in the presence of fructose, a GLUT5 ligand, or mannan, which is poorly metabolized both in vitro and in vivo.

[0155] 19 is a graph showing the results of measuring the concentrations of acetic acid, propionic acid, and butyric acid produced by Bp cultured on various carbon sources. As a result, Bp produced acetic acid as it grew, but did not produce propionic acid or butyric acid.

[0156] [Experimental Example 14] (Study on GPR41 Ligand) Acetic acid was focused on as a GPR41 ligand that induces SP. Figure 20 shows the results of STC-1 cells treated with vehicle (Veh) or each SCFA for 6 hours, followed by glucose treatment for 1 hour, and the intracellular Ca 2+The graph shows the results of measuring the concentration and secretion of GLP1 in STC-1 cells in the presence of glucose (n=8 for each group). 2+ increased the concentration and GLP1 production.

[0157] The addition of propionate and butyrate significantly increased the intracellular Ca of STC-1 cells. 2+ However, as shown in Experimental Example 12, almost no propionic acid or butyric acid was detected in the uSI of Bp-gnotobiotic mice and Eg-gnotobiotic mice.

[0158] Acetate acts as an agonist of GPR41-Gαi signaling and cooperates with glucose-SGLT1 signaling to induce the gut-brain circuit.

[0159] [Experimental Example 15] (Investigation of the role of acetic acid in SP) To investigate the role of acetic acid in SP, a two-bottle preference test was conducted in GF mice using glucose + acetic acid and AceK + acetic acid (n = 4 per group). Figure 21 shows a schematic diagram outlining the experiment and a graph showing the results. It was notable that GF mice preferred glucose over AceK in the presence of acetic acid. This is in contrast to the results of Experimental Example 1, which was conducted in the absence of acetic acid.

[0160] Taken together, these findings suggest that glucose, the final product of various simple carbohydrates such as monosaccharides and sugars ingested by the host, is metabolized to acetate by the SP-induced microbiota in the uSI, and then transported to the EEC via the acetate-EEC GPR41-Gαi-dependent pathway, resulting in Ca2+ 2+ It has been shown to contribute to mobilization.

[0161] [Experimental Example 16] (Search for SP-inducing bacteria in humans) Since acetic acid produced by SP-inducing bacteria of uSI is necessary for mouse SP, SP-inducing bacteria in humans were searched for.

[0162] GF of Experimental Example 1 huThe contents of mouse uSI were cultured under various anaerobic conditions, and 10 types of bacteria, including Bifidobacterium pseudocatenulatum (Bpc), were identified. Furthermore, Bpc was transplanted into GF mice, and SP was measured. Figure 28 shows a schematic diagram outlining the experiment and a graph showing the results.

[0163] Figure 27 shows the genome structure of Bp, Eg, and Bpc, based on the results of whole genome sequence analysis, showing the presence of genes encoding transporters in each bacterium and information on the location of the genes. In Figure 27, the shaded genes indicate the transporter genes in each bacterium.

[0164] Whole genome sequencing confirmed that Bpc is genetically closely related to Bp, and both possess genes necessary for acetate production, monosaccharide transport, and carbohydrate degradation. Bpc ) won the SP.

[0165] Bp and Eg were shown to have genes for several monosaccharide transporters. Furthermore, it was confirmed that Bp and Eg possess the complete set of genes required for acetate production, but did not possess the genes required for butyrate or propionate production.

[0166] Furthermore, it was revealed that the lactic acid bacteria strain identified in Experimental Example 8 possesses genes for several monosaccharide transporters, but lacks genes necessary for producing SCFAs including acetic acid.

[0167] CaZyme analysis revealed that Bp and Eg possessed various carbohydrate-degrading enzymes, including glycoside hydrolases (GH) 3, GH43, and GH13, which hydrolyze simple carbohydrates such as starch, as well as GH51, GH29, and GH32. In contrast, the five lactic acid bacteria strains did not possess GH3 or GH43, but did possess GH13 and GH65. This suggests that all seven strains can utilize simple carbohydrates using GH13, the largest amylolytic enzyme family.

[0168] The above results indicated that bacteria having a genomic gene structure similar to that of mouse Bp and human Bpc, as shown in Figure 27, and the seven strains of lactic acid bacteria isolated in Example 8 may confer sugar preference.

[0169] Experimental Example 17 (Study on Mice Fed a High Fat Diet) B6 mice were fed a normal diet (ND) or a high fat diet (HFD) for 4 weeks, and the amount of Bp in the jejunal contents was evaluated.

[0170] The left graph in Figure 22 shows the results of evaluating Bp levels in jejunal contents by 16S qPCR. The results revealed that Bp levels in uSI were significantly reduced in mice fed a high-fat diet.

[0171] Furthermore, B6 mice fed either a ND or HFD for 4 weeks were subjected to a two-bottle preference test for glucose and AceK (n = 7 per group). The graph in the center of Figure 22 shows the results of the two-bottle preference test. As a result, mice fed a high-fat diet lost SP, in contrast to mice fed a normal diet.

[0172] Obese mice were fed a HFD for 4 weeks and then orally administered Bp for an additional 2 weeks while continuing the HFD diet, and SP was measured. Control mice were given Gifu anaerobic medium (GAM) instead of Bp. The graph on the right in Figure 22 shows the results of a two-bottle preference test. SP was restored in the Bp-treated group, but not in the Bp-untreated group.

[0173] These results suggest that a high-fat diet abolishes sugar preference (SP) through Bp depletion in the upper small intestine (uSI).

[0174] [Experimental Example 18] (Study of Mice Fed a High-Fat Diet) Figure 23 is a schematic diagram outlining the experiment and a graph showing the results. A two-bottle free-choice model (glucose and AceK, GA group; glucose and glucose, GG group) was established in mice fed a modified HFD (mHFD) with or without Bp administration. After 4 weeks of mHFD administration, B6 mice were administered GAM or Bp daily. The mice then underwent a two-bottle preference test (n = 6 per group). The mHFD uses maltodextrin instead of the sucrose contained in standard HFD, reducing the impact of the original sweetness of the sucrose-containing HFD. As a result, SP disappeared in mice fed the mHFD for 4 weeks, while it was restored in mice orally administered with Bp.

[0175] Experimental Example 19 (Investigation of the effect of SP-inducing bacteria on glucose tolerance) B6 mice were fed mHFD for 4 weeks, then fed mHFD for another 4 weeks, and treated according to the following four groups (n=6 per group).

[0176] In the Bp-unadministered GG group, mHFD-fed mice were orally inoculated with GAM every day and were allowed to freely take glucose solution (GG bottle).

[0177] In the Bp-unadministered GA group, mHFD-fed mice were orally inoculated with GAM every day and were allowed to freely consume glucose solution and AceK solution (GA bottle).

[0178] In the Bp-administered GG group, mHFD-fed mice were orally inoculated with Bp every day and were allowed to freely take glucose solution (GG bottle).

[0179] In the Bp-administered GA group, mHFD-fed mice were orally inoculated with Bp every day and were allowed to freely consume glucose solution and AceK solution (GA bottle).

[0180] The left side of Fig. 24 is a graph showing the total daily water intake for each group, while the center and right sides of Fig. 24 are graphs showing the intake of glucose solution or AceK solution for each group.

[0181] As a result, there was no difference in the total intake of the two bottles among the four groups (Bp-untreated GG group, Bp-treated GA group, Bp-untreated GG group, and Bp-treated GA group). The Bp-untreated GG group chronically consumed twice as much glucose as the Bp-untreated GA group (Figure 24, upper, center and right). Notably, only the Bp-untreated GA group chronically consumed AceK and glucose equally due to the loss of SP (Figure 24, upper, center and right). In contrast, the Bp-treated GA group chronically consumed the same level of glucose as the Bp-treated GG group due to the recovery of SP (Figure 24, lower, center and right).

[0182] The upper graph in Figure 25 shows the results of an oral glucose tolerance test (OGTT) performed on day 18 from the start of the experiment. The lower graph in Figure 25 shows the results of an insulin tolerance test (ITT) performed on day 23 from the start of the experiment. As a result, the Bp-unadministered GA group showed worsening of the OGTT and ITT.

[0183] The Bp-administered GA group and the Bp-administered GG group showed improvements in OGTT and ITT compared with the Bp-unadministered GA group that had been chronically taking AceK (FIG. 25).

[0184] Figure 26 is a graph showing the results of measuring serum concentrations of insulin, LPS, GLP1, and leptin in each group on day 28. Type 2 diabetes mellitus (T2DM) is well-known to be characterized by insulin resistance and increased intestinal permeability. Consistent with the deterioration of glucose tolerance, the Bp-untreated GA group showed significantly elevated serum insulin and lipopolysaccharide (LPS) concentrations compared with the other three groups. However, no significant changes were observed in serum GLP1 and leptin concentrations among the four groups.

[0185] The results of this study are summarized in a schematic diagram in Figure 29. These results demonstrate that the acetate-producing microbiota in the upper small intestine is required for the establishment of the SP, as GLP1-producing EECs sense acetate in a GPR41-Gαi-dependent manner via the gut-brain axis and the GLP1-R-expressing afferent vagus nerve.

[0186] [Experimental Example 20] (Study 2 on microorganisms causing SP) Microorganisms causing SP were further investigated, and attention was focused on Lactobacillus casei (Lc) and Bifidobacterium bifidum (Bb).

[0187] Lactobacillus casei transplanted into GF mice (GF Lc mice) and mice in which Bifidobacterium bifidum was transplanted into GF mice (GF Bb Mice) were prepared and subjected to a two-bottle preference test.

[0188] Figure 30 is GF Lc 30 is a graph showing the results of the two-bottle preference test. The left graph in FIG. 30 is a graph showing the results of the two-bottle preference test. The center and right graphs in FIG. 30 are graphs showing the results of the GF on days 1 and 3. Lc 1 is a graph showing the amounts of glucose solution and AceK solution consumed by mice.

[0189] Figure 31 is GF Bb 31 is a graph showing the results of the two-bottle preference test. The left graph in Fig. 31 is a graph showing the results of the two-bottle preference test. The center and right graphs in Fig. 31 are graphs showing the results of the GF on days 1 and 3. Bb 1 is a graph showing the amounts of glucose solution and AceK solution consumed by mice.

[0190] As a result, it was revealed that Lactobacillus casei and Bifidobacterium bifidum have the ability to induce sugar preference.

[0191] According to the present invention, a technique can be provided for controlling sugar preference and thereby controlling sugar intake, metabolism, and reward.

Claims

1. An agent for controlling sugar intake, metabolism, and reward that contains lactic acid bacteria or bifidobacteria as active ingredients.

2. The sugar intake, metabolism, and reward control agent according to claim 1, wherein the lactic acid bacteria or bifidobacteria are bacteria having the genome structure shown in Figure 27.

3. The sugar intake, metabolism and reward control agent according to claim 2, wherein the lactic acid bacteria are Lactobacillus or Enterococcus, and the bifidobacteria are Bifidobacterium.

4. The sugar intake, metabolism and reward control agent according to claim 3, wherein the Lactobacillus bacterium is Lactobacillus casei, the Enterococcus bacterium is Enterococcus gallinarum, and the Bifidobacterium bacterium is Bifidobacterium pseudolongum, Bifidobacterium pseudocatenulatum or Bifidobacterium bifidum.

5. A sugar intake / metabolism / reward regulator according to any one of claims 1 to 4, having the effect of preventing or treating lifestyle-related diseases.

6. A food composition for preventing or improving lifestyle-related diseases, comprising the sugar intake / metabolism / reward regulator described in any one of claims 1 to 4.

Citation Information

Patent Citations

  • Glucose metabolism improving composition

    JP2021031408A

  • Christensenellaceae bacteria including Christensenella minuta and uses thereof

    JP2022513154A

  • Lactic acid bacteria, hypoglycemic agent derived from same, therapeutic agent for diabetes, and food or beverage

    WO2018034047A1

  • Composition for promoting the secretion of FGF21

    WO2019180964A1